Diabetic Gastroparesis Pipeline Insight
DelveInsight’s, “Diabetic Gastroparesis -Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diabetic Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Diabetic Gastroparesis Understanding
Diabetic Gastroparesis (DGp): Overview
Gastroparesis affects how the stomach moves food into the intestines and leads to bloating, nausea, and heartburn. When diabetes causes the condition, doctors call it diabetic gastroparesis. Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes. During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.
Signs and symptoms of gastroparesis vary in severity from person to person and may include any combination of the following:
- Nausea and vomiting, particularly of undigested food
- feeling full after eating very little
- loss of appetite
- unintentional weight loss
- unstable blood sugar levels
- gastroesophageal reflux
- stomach spasms
Diabetic gastroparesis is diagnosed by the presence of upper GI symptoms suggestive of delayed gastric emptying in a diabetic patient, exclusion of mechanical obstruction that could cause upper GI symptoms and the demonstration of delayed gastric emptying. In addition to the medical history and physical examination, various diagnostic techniques can be used. Obstruction caused by an intra-abdominal mass may be excluded by diagnostic imaging.
One or more of the following tests can be used to confirm the diagnosis of diabetic gastroparesis: Barium X-ray, Barium beefsteak test, Radioisotope gastric-emptying scan, Gastric manometry and others.
The development of gastroparesis is associated with poor glucose control, and the goal of optimal glycemic control needs to be emphasized. The usual treatments for Diabetic gastroparesis include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents, as discussed in the following sections.
Although the majority of patients have mild-to-moderate disease that can be managed effectively using these measures, a small percentage of patients have severe Diabetic gastroparesis that is characterized by inadequate oral intake, malnutrition, weight loss and frequent hospitalizations. Non-glycemic endocrine issues related to Diabetic gastroparesis include mineral and vitamin deficiency, low bone mass, hypogonadism and amenorrhea related to undernourishment in severe gastroparesis.
Diabetic Gastroparesis Emerging Drugs Chapters
This segment of the Diabetic Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Gastroparesis Emerging Drugs
- Nimacimab: Bird Rock Bio, Inc.
Nimacimab, a cannabinoid receptor one (CB1) inverse agonist monoclonal antibody, is being developed by Bird Rock Bio utilising its proprietary iCAPS platform, for the treatment of various fibrotic, inflammatory, and metabolic diseases, including non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, diabetic gastroparesis.
- TAK-906: Millennium Pharmaceuticals, Inc. / Takeda
TAK-906 is being tested to treat people who have symptomatic idiopathic or diabetic gastroparesis under a Phase II clinical trial. TAK‐906 is designed to retain the dopamine receptor antagonist profile and minimal central nervous system (CNS) penetration of domperidone whilst avoiding the cardiac effects. The study will enroll approximately 280 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups (in 1:1:1:1 ratio) which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need).
Relamorelin is a pentapeptide ghrelin receptor agonist with pro‐kinetic properties, which significantly accelerated gastric emptying and improved symptoms in patients with diabetic gastroparesis in phase 2 trials. Ghrelin receptor agonists may stimulate gastric contractions and enhance gastric emptying.
However, they may also increase glycaemia, in part by reducing insulin secretion, stimulating growth hormone release or enhancing carbohydrate absorption. Compared with native ghrelin, relamorelin has been shown to exhibit enhanced potency and plasma stability, with a terminal half‐life in humans of approximately 4.5 hours.
Further product details are provided in the report……..
Diabetic Gastroparesis: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Gastroparesis
There are approx. 10+ key companies which are developing the therapies for Diabetic Gastroparesis. The companies which have their Diabetic Gastroparesis drug candidates in the advanced stage, i.e. phase III and Phase II include, Bird Rock Bio, Inc., Millennium Pharmaceuticals, Inc., Takeda, Allergan, Vanda Pharmaceuticals, CinDome Pharma, Inc., Neurogastrx, Inc.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Diabetic Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diabetic Gastroparesis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Gastroparesis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Gastroparesis drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Gastroparesis.
- April 2020: Relamorelin showed acceptable safety and tolerability in phase 2 trials. Relamorelin may elevate blood glucose: this should be managed proactively in relamorelin‐treated patients. Among 204 phase 2a and 393 phase 2b patients, respectively, 67% and 62% were female, and 88% and 89% had type 2 diabetes. Proportions of patients reporting serious AEs were similar across treatment groups, as were those with ≥1 treatment‐emergent AE (TEAE).
- July 2020: Tradipitant improves nausea, vomiting in gastroparesis. Tradipitant correlated with statistically and clinically meaningful improvements in nausea and decreased vomiting in patients with idiopathic or diabetic gastroparesis, according to results from Gastroenterology. The effect of tradipitant in achieving complete response in nausea but also improving overall symptoms may suggest a disease modifying effect through an action to the local neuromuscular network as well as the central nervous system centers for nausea and vomiting.
- Diabetic Gastroparesis Report Insights
- Diabetic Gastroparesis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Diabetic Gastroparesis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Gastroparesis drugs?
- How many Diabetic Gastroparesis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Gastroparesis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Gastroparesis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Gastroparesis and their status?
- What are the key designations that have been granted to the emerging drugs?